Chapter 31: Porphyrins & Bile Pigments

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to The Deep Dive.

Today we are taking a stack of source material and diving deep into one of the most, well,

foundational and dramatically cyclical processes in human chemistry.

We're talking about the story of porphyrins and bile pigments.

Exactly.

It might sound super technical, but what we're really exploring is the full life cycle of heme, from its elaborate creation all the way to its carefully managed breakdown.

And more importantly, what happens to the human body when either of those stages goes catastrophically wrong?

Our mission today is to give you a shortcut to understanding the elegance of this pathway, starting with the star of the show,

heme.

Heme is an iron -containing porphyrin.

It's the essential working part of countless hemoproteins.

Right.

We're talking about your oxygen carriers, things like hemoglobin and myoglobin.

And the core components of your cellular tower plants, like cytochrome C.

Don't forget the critical defense systems, too.

The detoxifying enzyme cytochrome P450 in catalyst.

Heme is, and this isn't an exaggeration, the foundation upon which oxygen life is built.

And because heme is involved in, well, virtually every cellular function,

failures in its metabolism create two really distinct and major classes of clinical problems.

They really do.

On one side, we have the porcerias.

These are rare, often devastating genetic diseases caused by mistakes in heme synthesis.

And on the other side?

On the other side, we have jaundice, a much more common problem that results from errors in heme degradation and the excretion of its breakdown product, bilirubin.

For you, the learner, the goal today is clarity.

We want you to walk away knowing exactly how a deficiency in one tiny enzyme can cause, say, acute abdominal pain or severe photosensitivity.

Or why a simple blood test measuring direct versus indirect bilirubin is one of the most powerful diagnostic tools in medicine.

It all comes back to tracing the cause and effect along the pathway.

So let's start with the building block itself, the porphyrin structure.

It's essentially a specialized ring molecule, right, made of four smaller pyrrole rings all linked together.

That's the basic idea.

You don't need to memorize the formula, just know its function.

That cyclic structure makes it the perfect organic cage ready to trap a metal ion right in the middle.

It's a fantastic metal chelator.

It is.

When a porphyrin grabs magnesium, you get chlorophyll, the green pigment implants.

When it grabs iron, specifically ferrous iron, F2 +, you get heme.

You mentioned the diverse functions of heme.

Does the structure of the heme molecule itself ever change depending on its job?

It does, slightly.

And this is where it gets really interesting functionally.

Most heme is what we call heme B.

It easily associates with and dissociates from its protein.

Okay.

But then you have heme C, which you find in, for instance, cytochrome C.

Heme C forms these strong covalent bonds, thioethers, links to its APA protein.

So it's basically locked in place.

Exactly.

That structural difference means heme C isn't going anywhere, ensuring maximum stability.

And if you think about the bigger picture, this is vital for something like the electron transport chain, where that iron absolutely has to stay in position to pass electrons reliably.

That makes perfect sense.

The job determines the structural commitment.

Okay, so let's trace the journey of making this complex molecule.

We know most of it happens in bone marrow cells for hemoglobin, but what about the rest?

And where inside the cell?

It's a two -location job, a classic example of cellular teamwork, really.

It starts and finishes in the mitochondria, but the middle steps, they happen out in the cytosol.

And while the bone marrow handles most of it?

About 85%, yeah.

The liver, the hepatocytes, is responsible for most of the rest, primarily to supply the crucial cytochrome P450 enzymes.

And critically, mature red blood cells have no mitochondria.

So they can't make heme?

They're completely incapable of it.

Okay, let's get into the production line.

Where do the raw materials come from?

They're actually simple metabolic intermediates.

You've got sexinol CoA.

Which you might remember from the TCA cycle.

Ovarian one, and the amino acid glycine.

In the mitochondrial matrix, these two condense to form gaminolivelinate, or ALA.

And this first step is catalyzed by ALA synthase, or ALAS.

The source mentions two versions, ALAS 1 and ALAS 2.

Why is ALAS 1, the liver version, the most clinically important one here?

Because ALAS 1 is the master switch.

It catalyzes the first committed step in the hepaticane biosynthesis, which makes it the rate -limiting enzyme.

So everything hinges on its activity.

Exactly.

And that makes it the primary target for regulation, which we'll definitely get to in a moment.

So ALA is made in the mitochondria, but then it immediately moves out to the cytosol.

What happens next?

Once it's in the cytosol, two molecules of ALA combine.

They form prophoblinogen, or PVG, a crucial intermediary.

This reaction is catalyzed by ALA dehydratase, which is a zinc -containing enzyme.

And here, here's where we hit our first major clinical hazard.

Okay, what is it?

Well, ALA dehydratase is extremely sensitive to inhibition by heavy metals.

You mean like lead?

Specifically lead.

When lead is present, this enzyme is effectively shut down, causing a backup of ALA.

This pathway block contributes directly to some of the really severe neurological symptoms you see in lead poisoning.

Wow.

That's a powerful illustration.

A tiny enzyme block leads to nervous system pathology.

What about the rest of the cytosolic chain?

The remaining steps in the cytosol are all about building and refining that ring structure.

Four PVG molecules join up and cyclize to form europorphyrinogen III.

That's the asymmetric physiologically correct one.

And then?

Then, through a decarboxylation step, europorphyrinogen III is converted to coproporphyrinogen III.

Coproporphyrinogen III then heads back into the mitochondria for the final push.

Exactly.

Inside the mitochondria, two more oxidation steps take place, converting it first to protoporphyrinogen III and then to protoporphyrin III.

This brings us to the final necessary step.

Putting the iron in.

Incorporating the iron.

Ferrous iron, F2 +, is inserted into protoporphyrin III to form heme.

This reaction is catalyzed by ferrochelatase, also known as heme synthase.

And let me guess, this enzyme is also vulnerable to lead poisoning.

You got it.

So we have two key enzymes in the pathway, both sensitive to lead.

That's why lead poisoning causes such a profound disruption in heme production.

Let's circle back to regulation.

You said AlS1 is the master switch in the liver.

How exactly does the body stop the production line when it has enough heme?

It's a very elegant negative feedback loop.

The end product, heme itself, physically acts as a repressor.

How does that work?

When heme levels are high, it binds to a special protein, an apropressor, which then shuts down the synthesis of AlS1.

It prevents its transcription, its translation, and even its movement into the mitochondria.

High heme equals low AlS1, which slows production way down.

So what happens when we manipulate that system with, say, drugs?

This is critical because it's the immediate clinical link to the porphyrious.

If you take drugs like barbiturates, these compounds require a massive amount of cytochrome P450 to be metabolized.

Which is a heme -dependent enzyme.

Right.

So to handle the drug load, the cell ramps up P450 synthesis, which rapidly consumes the existing intracellular heme pool.

Though heme levels plummet.

They plummet.

And when that happens, the negative regulation on AlS1 is released.

It's what we call derepressed.

This causes a surge in AlS1 production, pushing the whole synthesis pathway into overdrive.

And the problem isn't making heme, it's what?

The problem is that if there's a subsequent enzyme defect further down the line, this overproduction leads to a massive accumulation of toxic heme precursors like ALA and PBG.

And that is what causes an acute porphyria attack.

That brings us directly to the pathology.

But before we list the specific diseases, we need to understand the chemistry of the pathology itself.

What's the difference between porphyrins and porphyrinogens, and why does it matter for the patient?

It's all about light absorption.

The intermediates we've been talking about, like uroporphyrinogen, are called porphyrinogens.

They're colorless, they're harmless, because they lack the conjugated double bonds needed to absorb light.

But the body is leaky.

Exactly.

When these porphyrinogens accumulate because of an enzyme block, they readily auto -oxidize into true porphyrins.

And porphyrins do have that conjugated system.

Which makes them colored.

Vibrantly colored.

And gives them a special ability to absorb light, especially around 400 nanometers.

This is called the soret band.

It's why they fluoresce bright red under UV light.

And when a porphyrin absorbs light, that energy release is what causes the symptoms.

When these accumulated porphyrins in the skin or tissues are hit by visible light, they get energized and react with oxygen, generating highly destructive oxygen radicals.

These radicals injure subcellular organelles, causing severe skin damage, blistering, scarring, all the acute symptoms you see in the porphyrias.

So let's look at the classic breakdowns.

In acute intermittent porphyria, or AIP, the block is in hydroxymethylbelanes synthase.

What are the clinical signs?

The classic triad for AIP is acute unexplained abdominal pain, coupled with severe neuropsychiatric symptoms.

Anxiety, confusion, psychosis.

These symptoms are thought to be caused by the neurological toxicity of those accumulated precursors, ALA and PBG.

And the lab test gives it away.

It does.

Massively elevated ALA and PBG in the urine.

Then you have the condition that historically gave rise to

the werewolf myth, congenital erythropoetic porphyria.

This is a devastating disease.

The defect is in uroporphyrinogen, the third, synthase, which leads to the accumulation of uroporphyrin, the first.

These high levels cause extreme painful photosensitivity, severe blistering, skin disfigurement, and even tooth discoloration.

And the folklore connection.

It's based on people with this disorder being pale, highly light sensitive, and suffering from facial disfigurement.

And we can't forget the acquired defect we mentioned, lead poisoning.

It hits both ALA dehydratase and ferrocellatase.

Right, which results in a dual accumulation of ALA and coproporphyrin in the urine and protoporphyrin in the red blood cells.

So for managing these acute porphyria attacks, the treatment seems pretty straightforward.

You just have to shut down ALS1.

That's the goal.

You give the patient the end product.

You give them heme.

It restores the feedback loop, represses ALS1, and quickly stops the flow of those toxic precursors.

Okay, shifting gears entirely now.

Let's talk about the destruction phase heme catabolism.

We are replacing something like 200 billion red blood cells every single day.

Which means we're turning over about 6 grams of hemoglobin.

The globin gets recycled, the iron is saved, but that big porphyrin ring, it has to be dismantled.

Where does that happen?

Mainly in specialized cells in the spleen and liver.

It starts when the porphyrin ring, in its ferric form called hemin, is cleaved by an enzyme called heme oxygenase.

It's an oxidation reaction that opens the ring.

And the product is?

The product is biliverdin, which is a vivid green pigment, plus carbon monoxide and the released iron.

So if you've ever had a bruise, you've seen this biochemistry play out in real time.

Absolutely.

That initial purple -blue of a hematoma, that's hemin.

Then the green stage is biliverdin.

After that, an enzyme called biliverdin reductase takes that green biliverdin and reduces the central bridge.

Converting it into the final yellow product?

Bilirubin.

Exactly.

The bruise turns yellow right before it vanishes.

Now bilirubin is the pigment responsible for jaundice, but it has a problem.

It's incredibly hydrophobic, water insoluble.

How does it get from the breakdown site to the liver for processing?

It has to hitch a ride.

Bilirubin travels bound tightly to serum albumin.

Now albumin is a reliable carrier, but this binding is a huge clinical concern, especially in neonates.

Why is that?

Because certain drugs, like some antibiotics,

can displace bilirubin from albumin.

If free unbound bilirubin levels get too high, it can cross the blood -brain barrier.

And that leads to the risk of chronicteris, or bilirubin encephalopathy, which is a profound neurological injury.

So the liver's job is to detoxify this molecule.

How does it do that?

In three essential coordinated stages.

First, uptake.

The liver cell facilitates transport of bilirubin off the albumin and into the hepatocyte.

Inside the cell, it immediately binds to cytosolic proteins, which prevents it from leaking back into the blood.

Okay, step one is uptake.

What's step two?

Second,

conjugation.

Since bilirubin is hydrophobic, the liver has to make it water -soluble so it can be excreted.

It does this by attaching two sugar molecules to glucuronosyl moieties.

This is done by the enzyme bilirubin UDP glucuronosyl transferase.

And the resulting molecule is bilirubin deglucuronide.

And this is what we call direct bilirubin.

And the final hurdle.

Third, secretion.

You've made this nice water -soluble molecule, but you have to get it out of the liver cell and into the bile duct.

Correct.

That's handled by an active transport mechanism, a protein called MO8, the multi -specific organic anion transporter.

You can think of it as the high -security door for the liver.

And what's fascinating here is that this MO8 -mediated secretion step is typically the rate -limiting step for the entire process.

Once that direct bilirubin is in the bile, it heads into the intestine.

What happens there?

It's the bacteria's job.

In the large intestine, bacteria remove the glucuronal sugars and then they chemically reduce the bilirubin to a series of colorless compounds called urobilinogens.

And these are eventually excreted.

Most are oxidized to colored urobilins, which are what gives feces its color.

A small amount gets reabsorbed into the circulation and recycled, the interohepatic loop, with any excess being filtered and appearing in the urine.

So when plasma bilirubin exceeds 2 to 2 .5 milligrams per deciliter, it leaks into the tissues and you turn yellow jaundice.

This brings us back to that critical distinction, direct versus indirect bilirubin.

Why is that so important for diagnosis?

Because it immediately tells you where the problem is located.

Indirect bilirubin is the unconjugated hydrophobic form.

Remember, this is the one that's fat -soluble and can cross the blood -brain barrier.

And direct bilirubin is the water -soluble conjugated form.

It's the only one that can dissolve and appear in the urine.

Okay, let's use that knowledge to pinpoint the three main causes of jaundice.

First, prehepatic jaundice.

This means the problem is happening before the liver.

The most common cause is massive overproduction, usually from hemolytic anemia.

Your red blood cells are being destroyed too quickly.

The liver is healthy, but it's just overwhelmed.

So the result is?

Markedly increased indirect bilirubin.

Crucially, you will find no bilirubin in the urine, but you will see increased urobilinogen in the urine because the liver is working overtime, processing all that excess.

Okay.

Second, hepatic jaundice.

This is damage to the liver itself, like hepatitis.

Right.

Liver damage messes up all three steps uptake, conjugation, and secretion.

So what you see are high levels of both direct and indirect bilirubin in the blood.

The results for urine are variable, depending on how badly the liver is damaged.

And finally, the cleanest clinical picture, post -hepatic jaundice, an obstruction after the liver.

A gallstone or a tumor blocking the bile duct.

If the duct is blocked, that conjugated, water -soluble, direct bilirubin can't be secreted.

It regurgitates back into the bloodstream, leading to a massive increase in direct bilirubin.

And because no pigment gets into the intestine.

The stool is pale.

And because the conjugated bilirubin is water -soluble, it spills into the urine, giving you dark, frothy urine.

The crucial finding here is that while conjugated bilirubin is present in the urine,

urobilinogen, the bacterial product, is absent from the urine, confirming the total blockage.

That is the ultimate clinical shortcut.

And we can't forget the genetic and neonatal conditions that target this specific pathway.

Exactly.

The most common is neonatal physiologic jaundice.

It's transient, caused by accelerated red blood cell destruction after birth, combined with the immaturity of the liver's conjugating enzyme.

We manage this with blue -light phototherapy.

And the long -term genetic issues.

They're all about that transferase activity.

Cricular nijartype I is the complete absence of the enzyme, often fatal.

Gilbert syndrome, on the other hand, is relatively harmless.

You retain about 30 % of transferase activity.

And Dubin -Johnson syndrome.

That's a defect in that critical MO8 secretion protein, which causes conjugated bilirubin to back up into the blood.

So to bring this complex story full circle,

we started with the construction phase, driven by secanulcoA and glycine, and tightly regulated by allay S1 in the liver, a pathway that, when broken, causes the devastating porphyrius.

And we followed HaEN to its end -of -life recycling, where HaMA Oxygenase transforms it into the pigment bilirubin.

And the liver's job, which really defines the clinical outcomes, is to make bilirubin water soluble via conjugation and get it out via that MOA transporter.

The ultimate practical knowledge you gain today is the power of that split bilirubin measurement.

Remembering the difference between direct and indirect, especially when combined with looking at urobilinogen levels in the urine, provides the immediate diagnostic key.

It lets you solve whether a patient's jaundice is caused by simple hemolysis, liver cell failure, or a physical obstruction.

We've seen that genetic locks in the porphyrin pathway can lead to severe photosensitivity and neurological issues, tying back to the strange myth of the werewolf.

We know that accumulated porphyrins cause cell damage through light -induced oxygen radicals.

So here's a final thought.

If the lysosome is one target, what specific cellular organelle besides lysosome might be most vulnerable to this photodynamic damage in the nervous system, given that the final steps of synthesis where the damage often originates are mitochondrial?

Think about that link between the location of the pathway and the location of the resulting damage.

Thank you for joining us for this deep dive.